Further investigation of serum bradykinin and B1R levels in COVID-19 patients remains crucial to confirm whether B1R-mediated dysregulation of the bradykinin–kallikrein pathway occurs in COVID-19. The gene discussed is BDKRB1; the disease is COVID-19.